<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362147">
  <stage>Registered</stage>
  <submitdate>22/02/2012</submitdate>
  <approvaldate>28/02/2012</approvaldate>
  <actrnumber>ACTRN12612000247875</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of the fixed combination Timolol 0,5%/Travoprost 0,004% compared the concomitant administration to the single components.</studytitle>
    <scientifictitle>Effect of the fixed versus unfixed combination of timolol and travoprost on intraocular pressure in 40 Caucasian patients with primary open angle glaucoma or ocular hypertension in 6 months follow up period.</scientifictitle>
    <utrn>U1111-1128-3742</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Primary open angle glaucoma</healthcondition>
    <healthcondition>Ocular hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Use of timolol and travoprost in treatment of primary open angle glaucoma.
Arm 1-Timolol 0,5% twice daily was instilled for 30 days in 80 eyes
Arm 2- Timolol 0,5% twice daily and travoprost 0,004% once a day were instilled for 30 days.
Arm 3- Fixed combination of timolol 0,5% /travoprost 0,004% once a day were instilled for 30 days.
The mode of instillation of these treatments is self-administration</interventions>
    <comparator>Standard treatment consists of administration of eye drop to low intraocular pressure.
The timolol is self aministratione twice daily and it is the standard treatment
The travoprost is self admiistration once a day.
The fixed combination timolol/travoprost is administration once a day.
The duration of use of these treatments ic chronic.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduction of the intraocular pressure with different combination of eye drop. This is assessed by Goldmann  applanation tonometry.</outcome>
      <timepoint>At 30,60,90 days after treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maintain low intraocular pressure during 24 hour,using fixed combination timolol/travoprost once a day.
This is assessed by Goldmann  applanation tonometry.</outcome>
      <timepoint>At 120,180 days after treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients over 18 years with clinical diagnosis of primary open angle glaucoma or ocular hypertension who had been treated with any therapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Abnormal corneal sensation, condition preventing tonometry, ocular opacity or insufficient dilation preventing retinal evaluation, narrow anterior chamber angle, inflammatory ocular surface disease, anterior/posterior uveitis, ocular inflammation/infection, progressive retinal disease, significant ocular signs/symptoms, allergic conjunctivitis, significant visual field defect or progressive visual field loss within the last year, history of certain ocular surgeries, significant cardiovascular disease, and history of pulmonary disease including asthma.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/02/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Luigi Mazzeo,Md</primarysponsorname>
    <primarysponsoraddress>155 V.le del Policlinico, 00161  Rome</primarysponsoraddress>
    <primarysponsorcountry>Italy</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>"La Sapienza"</fundingname>
      <fundingaddress>155 V.le del Policlinico, 00161 Rome</fundingaddress>
      <fundingcountry>Italy</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Elena Pacella,MD</sponsorname>
      <sponsoraddress>155 V.le del Policlinico, 00161  Rome</sponsoraddress>
      <sponsorcountry>Italy</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Francesco Mazzeo,MD</othercollaboratorname>
      <othercollaboratoraddress>155 V.le del Policlinico, 00161  Rome</othercollaboratoraddress>
      <othercollaboratorcountry>Italy</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of our research was to  assess the safety and efficacy of changing antiglaucoma therapy to the timolol 0,5% / travoprost 0,004% fixed combination administered once daily, from previous monotherapies, in a group of 40 patients with open-angle glaucoma followed for a period of six months.The combination was a valid defense in the treatment of open angle glaucoma</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Committee of the Department of Ophthalmology of the University La Sapienza of Rome</ethicname>
      <ethicaddress>155 V.le del Policlinico, 00161  Rome</ethicaddress>
      <ethicapprovaldate>25/01/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Luigi Mazzeo,MD</name>
      <address>155 V.le del Policlinico, 00161  Rome  Italy</address>
      <phone>+39 0649975302</phone>
      <fax>+39 0649975304</fax>
      <email>rss.pompeiano@gmail.com</email>
      <country>Italy</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Luigi Mazzeo,MD</name>
      <address>155 V.le del Policlinico, 00161  Rome  Italy</address>
      <phone>+39 0649975302</phone>
      <fax>+39 0649975304</fax>
      <email>rss.pompeiano@gmail.com</email>
      <country>Italy</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>